You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 16, April 25, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •JAMA News Video
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (19)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Genetic Disorders
 •Ophthalmology
 •Macular Degeneration
 •Aging/ Geriatrics
 •Alert me on articles by topic

Association of CFH Y402H and LOC387715 A69S With Progression of Age-Related Macular Degeneration

Johanna M. Seddon, MD, ScM; Peter J. Francis, MD, PhD; Sarah George, MPH; Dennis W. Schultz, PhD; Bernard Rosner, PhD; Michael L. Klein, MD

JAMA. 2007;297:1793-1800.

Context  Studies have reported that single-nucleotide polymorphisms in the genes CFH and LOC387715 are associated with age-related macular degeneration (AMD).

Objective  To assess whether these genetic variants have prognostic importance for progression to advanced AMD and related visual loss.

Design, Setting, and Participants  Prospective analysis of 1466 white participants in the Age-Related Eye Disease Study (AREDS), a US multicenter clinical trial conducted from 1990 to 2001 with a mean follow-up time of 6.3 years. Age-related macular degeneration status was determined by grading of fundus photographs. Progression (n = 281) was defined as newly diagnosed advanced AMD (geographic atrophy, exudative disease, or AMD causing visual loss) in one or both eyes during the course of the study. Genotypic analysis was conducted in 2006.

Main Outcome Measure  Incidence rates of dry and neovascular advanced AMD.

Results  The CFH Y402H and LOC387115 A69S polymorphisms were each independently related to progression from early or intermediate stages to advanced stages of AMD, controlling for demographic factors, smoking, body mass index, and AREDS vitamin-mineral treatment assignment, with odds ratios (ORs) of 2.6 (95% confidence interval [CI], 1.7-3.9) for CFH and 4.1 (95% CI, 2.7-6.3) for LOC387715 for the homozygous risk genotypes (P<.001 for trend for each additional risk allele for both genes). The effect of LOC387715 was stronger for progression to neovascular disease (OR, 6.1; 95% CI, 3.3-11.2) compared with geographic atrophy (OR, 3.0; 95% CI, 1.4-6.5) relative to no progression for the homozygous risk state. The presence of all adverse factors (both risk genotypes, smoking, and body mass index ≥25) increased risk 19-fold. Smoking and high body mass index increased odds of progression within each risk genotype. Genetic plus nongenetic risk scores provided an area under the receiver operating characteristic curve of up to 0.78.

Conclusions  Common polymorphisms in the genes CFH and LOC387715 are independently related to AMD progression after adjustment for other known AMD risk factors. Presence of these polymorphisms plus AREDS vitamin-mineral treatment, smoking, and body mass index of 25 or higher identify patients who are highly susceptible to developing advanced stages of this visually disabling disease.


Author Affiliations: Ophthalmic Epidemiology and Genetics Service, Department of Ophthalmology, Tufts-New England Medical Center (Dr Seddon), Departments of Epidemiology (Dr Seddon) and Biostatistics (Dr Rosner), Harvard School of Public Health, Harvard Graduate School of Education (Ms George); and Channing Laboratory, Harvard Medical School (Dr Rosner), Boston; and Macular Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland (Drs Francis, Schultz, and Klein).


RELATED LETTER

Genetic Associations With Age-Related Macular Degeneration
Javier Damián
JAMA. 2007;298(14):1637.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Macular Degeneration: Risk Factors for Progression
Janey L. Wiggs
Arch Ophthalmol. 2007;125(9):1264-1265.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Variants in the 10q26 Gene Cluster (LOC387715 and HTRA1) Exhibit Enhanced Risk of Age-Related Macular Degeneration along with CFH in Indian Patients
Kaur et al.
IOVS 2008;49:1771-1776.
ABSTRACT | FULL TEXT  

Measurement of Factor H Variants in Plasma Using Variant-Specific Monoclonal Antibodies: Application to Assessing Risk of Age-Related Macular Degeneration
Hakobyan et al.
IOVS 2008;49:1983-1990.
ABSTRACT | FULL TEXT  

Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection
Baird et al.
Hum Mol Genet 2008;17:1299-1305.
ABSTRACT | FULL TEXT  

Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration
Spencer et al.
Hum Mol Genet 2008;17:971-977.
ABSTRACT | FULL TEXT  

Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism
Droz et al.
Br. J. Ophthalmol. 2008;92:513-517.
ABSTRACT | FULL TEXT  

Future Use of Genomics in Coronary Artery Disease
Damani and Topol
J Am Coll Cardiol 2007;50:1933-1940.
ABSTRACT | FULL TEXT  

Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits
Swaroop et al.
Hum Mol Genet 2007;16:R174-R182.
ABSTRACT | FULL TEXT  

Genetic Associations With Age-Related Macular Degeneration
Damian
JAMA 2007;298:1637-1637.
FULL TEXT  

Macular Degeneration: Risk Factors for Progression
Wiggs
Arch Ophthalmol 2007;125:1264-1265.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.